BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $8.31 and last traded at $8.04, with a volume of 26609 shares. The stock had previously closed at $7.99.
Several equities analysts recently issued reports on the company. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. BidaskClub downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th. Royal Bank of Canada reissued a “buy” rating and issued a $9.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $8.50 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $9.89.
The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.35. The stock has a market cap of $851.55 million, a PE ratio of -10.37 and a beta of 1.75.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 145.89%. The firm had revenue of $1.45 million during the quarter, compared to analyst estimates of $2.53 million. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.87 EPS for the current year.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total transaction of $71,314.00. Following the sale, the insider now directly owns 140,633 shares of the company’s stock, valued at approximately $1,018,182.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas R. Staab II sold 10,856 shares of the stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $7.84, for a total value of $85,111.04. Following the sale, the chief financial officer now directly owns 144,739 shares in the company, valued at $1,134,753.76. The disclosure for this sale can be found here. Insiders have sold a total of 25,815 shares of company stock worth $194,758 over the last ninety days. 4.50% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in BCRX. Warren Averett Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth about $171,000. Paloma Partners Management Co acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $174,000. Wells Fargo & Company MN grew its position in BioCryst Pharmaceuticals by 29.3% during the 1st quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 15,403 shares during the period. Spark Investment Management LLC acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $344,000. Finally, State of Wisconsin Investment Board grew its position in BioCryst Pharmaceuticals by 79.1% during the 2nd quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock worth $575,000 after purchasing an additional 44,300 shares during the period. 79.82% of the stock is currently owned by institutional investors.
BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.